Human induced pluripotent stem cell (iPSC)-based models are a valuable resource for studying disease mechanisms in vitro at the cellular level, screening potential new therapeutics, and investigating the propensity and mechanism for the development of toxic side effects caused by a drug treatment. Such iPSC-based models enable research to be performed under defined experimental conditions and in a reproducible manner. [Read more…]
Hamburg, Germany, June 5, 2019 — Evotec SE announced that its strategic alliance with Celgene Corporation (“Celgene”) has been expanded to include a new cell type triggering a payment of $9.0 m to Evotec.
Evotec and Celgene initiated the collaboration in December 2016 to identify disease-modifying treatments for a broad range of neurodegenerative diseases. Since then, the companies have achieved several milestones including advancement of one programme into lead optimisation as well as including additional cell lines and now a new cell type. [Read more…]
Takara Bio broke news that the Medical Products Agency (“MPA”), the Swedish national authority responsible for regulation of drug and medical products, granted the company a manufacturing license for derivation and banking of human embryonic stem (hES) cells to be produced under GMP conditions. The cells will be produced at Takara Bio’s manufacturing laboratory located in Göteborg, Sweden, within Takara Bio Europe’s facility.
The announcement caught my attention, because to the best of my knowledge, Takara Bio is the first company worldwide to offer this service for human ESCs.
Takara Bio’s Role with Human Pluripotent Stem Cells
The significance of this event is that Takara Bio is now capable of providing a safe, reliable source of hES cells for future cellular therapeutic development by sourcing starting material from FDA-compliant facilities according to FDA guidelines and leveraging its proprietary, feeder-free hES cell establishment method, which is animal- and human-component free. [Read more…]
Recent years have seen major advances in the clinical applications of iPSCs, with Cynata Therapeutics progressing the world’s first formal trial of an iPSC-derived cell therapeutic and demonstrating that CYP-001, its lead iPSC-derived mesenchymal stem cell (MSC) product candidate, met all safety and efficacy endpoints in its Phase 1 trial for GvHD.
With multiple physician-led iPSC studies also underway in Japan for applications ranging from Parkinson’s disease to heart disease, the iPSC market is poised to for burgeoning growth. There has also been dramatic progress with production and differentiation technologies related to iPSCs, as well as growing use of iPSCs within drug discovery, disease modelling, tissue engineering, and precision medicine. [Read more…]
Anyone who has ever watched a friend or loved one succumb to the slow degradation of Parkinson’s disease will understand the urge to cure it. Read on to learn more about how stem cells could be a possible treatment option for Parkinson’s disease.
In this article:
- What Causes Parkinson’s Disease?
- How Do Stem Cells Work?
- What Stem Cells Did Scientists Use to Accomplish This?
- What Are the Challenges of Using Stem Cells to Cure Parkinson’s?
- What Are the Benefits?